These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 45368)

  • 21. Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001 - 2009).
    Xiang YT; Kreyenbuhl J; Dickerson FB; Ungvari GS; Wang CY; Si TM; Lee EH; Chiu HF; Lai KY; He YL; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong MK; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
    Int J Clin Pharmacol Ther; 2012 Jul; 50(7):500-4. PubMed ID: 22541750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A long-term pilot study of pipothiazine palmitate in chronic schizophrenia.
    Villeneuve A; Pires A; Jus A; Lachance R; Drolet A
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):696-706. PubMed ID: 4404626
    [No Abstract]   [Full Text] [Related]  

  • 23. Atypical antipsychotics in the treatment of schizophrenia. Paper underrates patients' experience of extrapyramidal symptoms.
    Kerwin R
    BMJ; 2001 Apr; 322(7291):926-7; author reply 927-8. PubMed ID: 11302914
    [No Abstract]   [Full Text] [Related]  

  • 24. Extrapyramidal reactions in adolescents treated with high-potency antipsychotics.
    Chiles JA
    Am J Psychiatry; 1978 Feb; 135(2):239-40. PubMed ID: 23686
    [No Abstract]   [Full Text] [Related]  

  • 25. Treating extrapyramidal reactions: some current issues.
    Gelenberg AJ
    J Clin Psychiatry; 1987 Sep; 48 Suppl():24-7. PubMed ID: 2887554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
    Gerlach J
    J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current status of our knowledge of the neurotropic side effects of neuroleptic drugs].
    Sabbatini F; Pinessi L; Gentile S; De Mattei M; Portaleone P
    Minerva Psichiatr; 1983; 24(4):145-53. PubMed ID: 6145083
    [No Abstract]   [Full Text] [Related]  

  • 28. Akinesia and postpsychotic depression: a difficult differential diagnosis.
    Siris SG
    J Clin Psychiatry; 1987 Jun; 48(6):240-3. PubMed ID: 2884213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased extrapyramidal side effects and polypsichopharmacy in family practice outpatients.
    Holt RJ
    Bol Asoc Med P R; 1983 Aug; 75(8):351-2. PubMed ID: 6139115
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pilot study on oxaflumazine, a new piperazinated phenothiazine].
    Villeneuve A; Dogan K; Lachance R; Drolet A
    Int J Clin Pharmacol; 1972 Aug; 6(3):246-55. PubMed ID: 4405378
    [No Abstract]   [Full Text] [Related]  

  • 31. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Neu C; Dimascio A; Demirgian E
    Curr Ther Res Clin Exp; 1972 May; 14(5):246-51. PubMed ID: 4623975
    [No Abstract]   [Full Text] [Related]  

  • 32. Prophylaxis of antipsychotic-induced extrapyramidal side effects in east Indians: cultural practice or biological necessity?
    Dhavale HS; Pinto C; Dass J; Nayak A; Kedare J; Kamat M; Dewan M
    J Psychiatr Pract; 2004 May; 10(3):200-2. PubMed ID: 15330229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extrapyramidal side effects: a historical perspective.
    Rifkin A
    J Clin Psychiatry; 1987 Sep; 48 Suppl():3-6. PubMed ID: 2887555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aripiprazole and extrapyramidal symptoms.
    Lindsey RL; Kaplan D; Koliatsos V; Walters JK; Sandson NB
    J Am Acad Child Adolesc Psychiatry; 2003 Nov; 42(11):1268-9. PubMed ID: 14566162
    [No Abstract]   [Full Text] [Related]  

  • 35. Prophylactic antiparkinson drug use: I. Initial prophylaxis and prevention of extrapyramidal side effects.
    Lavin MR; Rifkin A
    J Clin Pharmacol; 1991 Aug; 31(8):763-8. PubMed ID: 1679062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
    Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
    Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders.
    Kim JH; Jung HY; Kang UG; Jeong SH; Ahn YM; Byun HJ; Ha KS; Kim YS
    Mov Disord; 2002 Nov; 17(6):1354-9. PubMed ID: 12465082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Non-extrapyramidal motor side-effects in long-term therapy with neuroleptics: an analysis of 99 patients].
    Ginzel I; Hilger E; Barnas C
    Wien Klin Wochenschr; 2002 Jan; 114(1-2):38-43. PubMed ID: 12407934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rehabilitation of the chronic schizophrenic patient: psychopharmacological aspects.
    Kristjansen P; Fog R; Munkvad I
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):54-8. PubMed ID: 14333
    [No Abstract]   [Full Text] [Related]  

  • 40. Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia.
    Correll CU
    J Clin Psychiatry; 2011 Jan; 72(1):e01. PubMed ID: 21272508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.